Fig. 2

Effect of blockade or stimulation of the EP1 receptor on functional outcomes after ICH. Antagonist (SC-51089, 10 µg/kg), agonist (17-pt-PGE₂, 0.3 mg/kg), or vehicle (saline) was administered subcutaneously at the onset of injury, 6 h post-ICH, and at 12-h intervals thereafter. Neurobehavioral testing was performed at 24, 48, and 72 h after ICH by individuals blinded to the treatment groups. No significant differences in baseline functioning were seen between the treatment groups on any of the neurobehavioral tests. a Grip strength testing showed that mice treated with 17-pt-PGE₂ had significantly improved forelimb strength at all testing time points post-ICH, whereas no significant differences were seen with SC-51089 treatment. b Mice treated with 17-pt-PGE₂ had significantly improved latency to fall on the hanging wire task at 24 h following ICH, whereas no significant differences were seen with SC-51089 treatment. c Mice in all treatment groups displayed similar performance on an accelerating rotarod after ICH. d Treatment with SC-51089 or 17-pt-PGE₂ did not affect post-ICH ambulatory activity. *p < 0.05 and **p < 0.01 when compared to the control group, n = 8–10 per group.